Hospital Corporation of China Ltd. has announced its unaudited consolidated financial results for the six months ended June 30, 2025. The company reported a revenue of RMB743 million, up 3.3% from RMB719.5 million during the same period last year. This increase was primarily driven by a rise in revenue from general hospital services. Adjusted gross profit for the period was RMB155 million, a decline of 4.2% compared to the previous year. Adjusted net profit stood at RMB70.6 million, down from RMB87.3 million in the first half of 2024. The adjusted gross profit margin decreased to 20.9% from 22.5%, while the adjusted net profit margin fell to 9.5% from 12.1%. In terms of segment performance, the general hospital services segment continued to be the primary revenue generator with RMB712.2 million, followed by hospital management services at RMB25.3 million, and sales of pharmaceutical products at RMB4.3 million. The company is exploring the establishment of regional hospital medical consortiums and plans to expand collaborations with advanced service providers in precision medicine. This initiative is aimed at enhancing supplementary services for patient families within the public basic healthcare system.